Close Menu

NEW YORK ─ Eurofins said on Tuesday that it has increased its revenue guidance for fiscal year 2020 to €5.3 billion ($6.44 billion), up from €5.0 billion established in March before COVID-19 disruptions started in Europe and North America.

The Luxembourg-based company said that in the second half of 2020, its core business, excluding COVID-19 clinical reagents and testing revenues, remained resilient, despite the impact of lockdowns in many geographies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.